Results 11 to 20 of about 3,216,105 (293)

Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis [PDF]

open access: greenJournal of Rheumatology, 2017
Pamela F. Weiss   +7 more
openalex   +2 more sources

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis [PDF]

open access: bronzeArthritis care & research, 2012
Jasvinder A. Singh   +29 more
openalex   +2 more sources

Effects of Abatacept in patients with rheumatoid arthritis and cancer risk [PDF]

open access: yesReviews in Clinical Medicine, 2023
Introduction: As a chronic autoimmune disease, Rheumatoid arthritis (RA) affects the joints. Studies have shown a complex and challenging link between cancer and RA.
Saba Homapoor   +2 more
doaj   +1 more source

Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil [PDF]

open access: bronzeArthritis care & research, 2016
Francisco de Assis Acúrcio   +7 more
openalex   +2 more sources

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2022
Background/Aims The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Kichul Shin   +14 more
doaj   +1 more source

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials

open access: yesArthritis Research & Therapy, 2023
Background This study sought to evaluate the efficacy and safety of tofacitinib in patients with rheumatoid arthritis with distinct treatment histories. Methods Pooled phase II/III trial data from patients who received tofacitinib 5 or 10 mg twice daily ...
John Tesser   +6 more
doaj   +1 more source

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2020
Background/Aims The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA ...
Kichul Shin   +23 more
doaj   +1 more source

Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. [PDF]

open access: bronzeJournal of Immunology, 1992
The cytokines IL-6, IL-1, and TNF play a key role in the pathogenesis of rheumatoid arthritis (RA) and initiate hepatic serum amyloid A (SAA) expression after injury.
Jean D. Sipe, Laura M. Bartle, L D Loose
openalex   +2 more sources

Home - About - Disclaimer - Privacy